Kiniksa Pharmaceuticals International, plc (KNSA) Stock Analysis
A live, multi-source view of Kiniksa Pharmaceuticals International, plc (KNSA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United Kingdom · 366 employees · kiniksa.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Kiniksa Pharmaceuticals International, plc (KNSA) had a market capitalization of $6.08B, a trailing P/E of 81.2 (forward 48.2) and a beta of 0.09; the shares traded in a 52-week range of $35.20 – $82.94 (120.0% over the year).
- Market cap
- $6.08B
- Enterprise value
- $5.56B
- Trailing P/E
- 81.2
- Forward P/E
- 48.2
- Price / book
- 9.29
- EPS (trailing)
- $0.96
- EPS (forward)
- $1.62
- Payout ratio
- 0.0%
- 52-week range
- $35.20 – $82.94
- 52-week change
- 120.0%
- Beta
- 0.09
- Average volume
- 738,585
- Shares outstanding
- 48.3M
- Short % of float
- 10.71%
- Profit margin
- 9.6%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Kiniksa Pharmaceuticals International, plc (KNSA) last closed at $77.91 (the last completed close before that scan).
Technicals at the scan: RSI 54 (neutral territory), price -1.2% versus its 20-day average, 20-day versus 50-day average spread +9.7%, MACD histogram -0.61.
Sentiment inputs: StockTwits 90% bullish; analyst consensus score 78/100.
Next scheduled company event: in 49 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of KNSA; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-07-31). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: G Bradley Cole (0B/1S). Who is trading what
RapidTradeView pick record
KNSA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Kiniksa Pharmaceuticals International, plc (KNSA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell KNSA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.